We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note
Read MoreHide Full Article
Adma Biologics (ADMA - Free Report) closed at $16.58 in the latest trading session, marking a +1.28% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.76%. Meanwhile, the Dow experienced a drop of 0.75%, and the technology-dominated Nasdaq saw a decrease of 1.01%.
Coming into today, shares of the infectious disease drug developer had lost 10.06% in the past month. In that same time, the Medical sector lost 3.35%, while the S&P 500 gained 4.31%.
Investors will be eagerly watching for the performance of Adma Biologics in its upcoming earnings disclosure. The company's upcoming EPS is projected at $0.13, signifying a 1200% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $107.25 million, indicating a 59.41% increase compared to the same quarter of the previous year.
Any recent changes to analyst estimates for Adma Biologics should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Right now, Adma Biologics possesses a Zacks Rank of #3 (Hold).
Investors should also note Adma Biologics's current valuation metrics, including its Forward P/E ratio of 33.41. This indicates a premium in contrast to its industry's Forward P/E of 22.58.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 88, positioning it in the top 35% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note
Adma Biologics (ADMA - Free Report) closed at $16.58 in the latest trading session, marking a +1.28% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.76%. Meanwhile, the Dow experienced a drop of 0.75%, and the technology-dominated Nasdaq saw a decrease of 1.01%.
Coming into today, shares of the infectious disease drug developer had lost 10.06% in the past month. In that same time, the Medical sector lost 3.35%, while the S&P 500 gained 4.31%.
Investors will be eagerly watching for the performance of Adma Biologics in its upcoming earnings disclosure. The company's upcoming EPS is projected at $0.13, signifying a 1200% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $107.25 million, indicating a 59.41% increase compared to the same quarter of the previous year.
Any recent changes to analyst estimates for Adma Biologics should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Right now, Adma Biologics possesses a Zacks Rank of #3 (Hold).
Investors should also note Adma Biologics's current valuation metrics, including its Forward P/E ratio of 33.41. This indicates a premium in contrast to its industry's Forward P/E of 22.58.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 88, positioning it in the top 35% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.